RVNC

0.00

100.00% -3.65

Handel nachbörslich: 3.66 3.66 +

Revance Therapeutics Inc (RVNC)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt RVNC? Forum Prognose

Schlusskurs vom Vortag:

$3.65

Offen:

24-Stunden-Volumen:

Relative Volume:

0.00

Marktkapitalisierung:

$381.02M

Einnahmen:

$234.04M

Nettoeinkommen (Verlust:

$-323.92M

KGV:

0.00

EPS:

-3.8

Netto-Cashflow:

$-223.46M

1W Leistung:

-100.00%

1M Leistung:

-100.00%

6M Leistung:

-100.00%

1J Leistung:

-100.00%

1-Tages-Spanne:

$0.00

1-Wochen-Bereich:

$0.00

$3.66

52-Wochen-Spanne:

$0.00

$7.56

Revance Therapeutics Inc Stock (RVNC) Company Profile

Firmenname

Revance Therapeutics Inc

Sektor

Healthcare (1176)

Branche

Biotechnology (678)

Telefon

(615) 724-7755

Adresse

1222 DEMONBREUN STREET, NASHVILLE, CA

Mitarbeiter

597

Twitter

@revance

Nächster Verdiensttermin

2024-11-04

Neueste SEC-Einreichungen

RVNC's Discussions on Twitter

Vergleichen Sie RVNC mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
RVNC Revance Therapeutics Inc	0.00	381.02M	234.04M	-323.92M	-223.46M	-3.80
VRTX Vertex Pharmaceuticals Inc	455.22	117.23B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	665.46	72.75B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	636.02	38.65B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	268.99	34.69B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	114.50	27.45B	3.30B	-501.07M	1.03B	-2.1146

Revance Therapeutics Inc Stock (RVNC) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-01-29	Herabstufung	Mizuho	Buy → Neutral
2024-01-09	Herabstufung	Goldman	Buy → Neutral
2023-08-16	Hochstufung	Exane BNP Paribas	Underperform → Neutral
2022-10-11	Eingeleitet	Morgan Stanley	Equal-Weight
2022-09-22	Eingeleitet	Goldman	Buy
2021-10-25	Herabstufung	Wells Fargo	Overweight → Equal Weight
2020-10-15	Bestätigt	Needham	Buy
2020-08-11	Fortgesetzt	Mizuho	Buy
2020-03-23	Herabstufung	Goldman	Buy → Neutral
2019-12-02	Eingeleitet	Goldman	Buy
2019-10-30	Hochstufung	Wells Fargo	Market Perform → Outperform
2019-06-11	Eingeleitet	Barclays	Overweight
2019-02-15	Eingeleitet	Wells Fargo	Market Perform
2019-02-14	Eingeleitet	H.C. Wainwright	Buy
2019-01-29	Eingeleitet	Stifel	Buy
2018-11-16	Hochstufung	Guggenheim	Neutral → Buy
2018-09-17	Herabstufung	JMP Securities	Mkt Outperform → Mkt Perform
2018-04-20	Bestätigt	Mizuho	Buy
2018-03-27	Eingeleitet	Needham	Buy
2018-03-05	Eingeleitet	Goldman	Buy
2018-01-09	Herabstufung	Guggenheim	Buy → Neutral
2017-12-06	Eingeleitet	Guggenheim	Buy
2017-12-06	Bestätigt	Mizuho	Buy
2017-11-27	Eingeleitet	Barclays	Overweight
2017-11-17	Eingeleitet	Mizuho	Buy
2017-08-22	Eingeleitet	JMP Securities	Mkt Outperform

Alle ansehen

Revance Therapeutics Inc Aktie (RVNC) Neueste Nachrichten

Feb 11, 2025

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesRVNC - PR Newswire

Feb 11, 2025

Deadline Alert: Revance Therapeutics, Inc. (RVNC) Investors - GlobeNewswire

Feb 11, 2025

2025-02-11 | Shareholders that lost money on Revance Therapeutics, Inc. (RVNC) should contact Levi & Korsinsky about pending Class ActionRVNC | Press Release - Stockhouse Publishing

Feb 11, 2025

Feb 10, 2025

2025-02-10 | Shareholders that Lost Money on Revance Therapeutics, Inc. (RVNC) Should Contact Levi & Korsinsky about Pending Class ActionRVNC | Press Release - Stockhouse Publishing

Feb 10, 2025

Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire

Feb 10, 2025

2025-02-10 | Levi & Korsinsky Notifies Shareholders of Revance Therapeutics, Inc. (RVNC) of a Class Action Lawsuit and an Upcoming Deadline | Press Release - Stockhouse Publishing

Feb 10, 2025

2025-02-10 | RVNC LAWSUIT ALERT: Levi & Korsinsky Notifies Revance Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline | Press Release - Stockhouse Publishing

Feb 10, 2025

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Revance Therapeutics, Inc.(RVNC) Shareholders - PR Newswire

Feb 10, 2025

Feb 09, 2025

Class Action Filed Against Revance Therapeutics, Inc. (RVNC)March 4, 2025 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire

Feb 09, 2025

2025-02-09 | Class Action Filed Against Revance Therapeutics, Inc. (RVNC)March 4, 2025 Deadline to JoinContact Levi & Korsinsky | Press Release - Stockhouse Publishing

Feb 09, 2025

Deltec Asset Management LLC Makes New $304,000 Investment in Revance Therapeutics, Inc. (NASDAQ:RVNC) - MarketBeat

Feb 09, 2025

Feb 08, 2025

StockNews.com Begins Coverage on Revance Therapeutics (NASDAQ:RVNC) - ETF Daily News

Feb 08, 2025

Revance Therapeutics, Inc. (NASDAQ:RVNC) Shares Sold by SG Americas Securities LLC - Defense World

Feb 08, 2025

Revance Therapeutics (NASDAQ:RVNC) Completes Merger with Crown Laboratories - Defense World

Feb 08, 2025

Crown Labs completes acquisition of Revance Therapeutics - MSN

Feb 08, 2025

Feb 07, 2025

Crown Laboratories Completes Acquisition of Revance Therapeutics - BioSpace

Feb 07, 2025

Major Aesthetics Industry Shakeup: Crown Labs Takes Over Revance in Strategic Power Move - StockTitan

Feb 07, 2025

Class Action Filed Against Revance Therapeutics, Inc. - GlobeNewswire

Feb 07, 2025

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance LawsuitRVNC - The Malaysian Reserve

Feb 07, 2025

StockNews.com Initiates Coverage on Revance Therapeutics (NASDAQ:RVNC) - MarketBeat

Feb 07, 2025

Crown Labs completes acquisition of Revance Therapeutics By Investing.com - Investing.com Nigeria

Feb 07, 2025

Feb 06, 2025

GLAZER CAPITAL, LLC Acquires Significant Stake in Revance Therap - GuruFocus.com

Feb 06, 2025

RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.

Feb 06, 2025